News Quantified

DNLI – denali therapeutics inc. (US:NASDAQ)

Denali Therapeutics (DNLI) had its "buy" rating reaffirmed by Jefferies Financial Group Inc..

Denali Therapeutics (DNLI) had its price target raised by BTIG Research from $32.00 to $36.00. They now have a "buy" rating on the stock.

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights [Yahoo! Finance]

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Denali Therapeutics (NASDAQ:DNLI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}